Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1999;30:1900-1906

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koistinaho, J.
Right arrow Articles by Hsu, C. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koistinaho, J.
Right arrow Articles by Hsu, C. Y.
Related Collections
Right arrow Animal models of human disease
Right arrow Gene expression
Right arrow Embolic stroke
Right arrow Neuroprotectors

(Stroke. 1999;30:1900-1906.)
© 1999 American Heart Association, Inc.


Original Contributions

Expression of Cyclooxygenase-2 mRNA After Global Ischemia Is Regulated by AMPA Receptors and Glucocorticoids

Jari Koistinaho, MD, PhD; Susanna Koponen, BS Pak H. Chan, PhD

From A.I. Virtanen Institute for Molecular Sciences, University of Kuopio (Finland) (J.K., S.K.); Department of Neurology, Kuopio University Hospital (Finland) (J.K.); and Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, Calif (J.K., S.K., P.H.C.).

Background and Purpose—Cyclooxygenase-2 (COX-2) is implicated in ischemic neuronal death. In focal ischemia, its mRNA induction is mediated through N-methyl-D-aspartic acid (NMDA) receptors and phospholipase A2. Because mechanisms of neuronal death involving COX-2 in global ischemia are unclear, we studied the time course and regulation of COX-2 expression in rat brain global ischemia.

Methods—Global ischemia was induced by a 4-vessel occlusion method. COX-2 mRNA levels were demonstrated with in situ hybridization and COX-2 protein with immunocytochemistry. Several animals were pretreated with MK-801, an NMDA receptor antagonist; 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX), an {alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist; and dexamethasone.

Results—In the cortex, the CA3 hippocampal region and dentate gyrus expression of COX-2 mRNA peaked at 4 to 8 hours, while in the CA1 region COX-2 mRNA levels were high at 4 to 24 hours. COX-2 protein was induced in the corresponding regions at 12 to 24 hours, but in the CA1 neurons the protein was still seen at 3 days. COX-2 mRNA induction in the cortex was inhibited by NBQX and dexamethasone and in CA1 neurons was inhibited by NBQX. MK-801 did not suppress COX-2 induction.

Conclusions—COX-2 is differentially induced in the cortex and hippocampal structures after global ischemia. The prolonged COX-2 expression in the vulnerable CA1 neurons is regulated by AMPA receptors, suggesting that COX-2 expression is likely to be associated with AMPA receptor–mediated neuronal death in global ischemia. Glucocorticoids may not be efficiently used to inhibit ischemia-induced COX-2 expression in the hippocampus.

Editorial Comment

Chung Y. Hsu, MD, PhD, Guest Editor

Department of Neurology, Washington University School of Medicine, St Louis, Missouri




This article has been cited by other articles:


Home page
FASEB J.Home page
Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman
Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats
FASEB J, June 1, 2006; 20(8): 1162 - 1175.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
C. E. Wood
Estrogen/Hypothalamus-Pituitary-Adrenal Axis Interactions in the Fetus: the Interplay Between Placenta and Fetal Brain
Reproductive Sciences, February 1, 2005; 12(2): 67 - 76.
[Abstract] [PDF]


Home page
Anesth. Analg.Home page
C. R. McCrory and S. G. E. Lindahl
Cyclooxygenase Inhibition for Postoperative Analgesia
Anesth. Analg., July 1, 2002; 95(1): 169 - 176.
[Full Text] [PDF]


Home page
StrokeHome page
P. A. Lapchak, D. M. Araujo, D. Song, and J. A. Zivin
Neuroprotection by the Selective Cyclooxygenase-2 Inhibitor SC-236 Results in Improvements in Behavioral Deficits Induced by Reversible Spinal Cord Ischemia
Stroke, May 1, 2001; 32(5): 1220 - 1225.
[Abstract] [Full Text] [PDF]